News & Events

Stay up to date with the latest

News

Learn the most recent news and follow our latest developments.

August 25, 2021

BridgeBio Pharma and LianBio Announce First Patient Treated in Phase 2a Trial of Infigratinib in Patients with Gastric Cancer and Other Advanced Solid Tumors

arrow-btn

August 2, 2021

LianBio Appoints Pascal Qian as General Manager of China

arrow-btn

June 2, 2021

Lyra Therapeutics and LianBio Announce Strategic Partnership and Exclusive License Agreement to Develop and Commercialize LYR-210 in Greater China and Other Asian Markets

arrow-btn

May 17, 2021

Landos Biopharma and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Omilancor and NX-13 in Greater China and Select Asian Markets

arrow-btn

May 12, 2021

Nanobiotix Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumore Types and Therapeutic Combinations in China and Other Asian Markets

arrow-btn

May 10, 2021

LianBio Appoints Yizhe Wang, Ph.D., as Chief Executive Officer

arrow-btn

March 29, 2021

Tarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 in Greater China for the Treatment of Demodex Blepharitis and Meibomian Gland Disease

arrow-btn

March 18, 2021

LianBio Announces Appointment of Yi Larson as Chief Financial Officer

arrow-btn

March 2, 2021

ReViral and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Sisunatovir in China

arrow-btn

December 1, 2020

LianBio Announces Clearance to Initiate in China the Phase 2a Trial of Infigratinib in Patients with Locally Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma with FGFR2 Gene Amplification

arrow-btn

November 19, 2020

Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in Greater China

arrow-btn

November 3, 2020

LianBio Announces Clearance to Initiate the Phase 3 PROOF Trial of Infigratinib in Patients with Locally Advanced or Metastatic Unresectable Cholangiocarcinoma with FGFR2 Gene Fusions in China

arrow-btn

October 29, 2020

LianBio Announces $310 Million Crossover Financing

arrow-btn

August 11, 2020

MyoKardia and LianBio Form Strategic Partnership to Develop and Commercialize Mavacamten Together in Greater China

arrow-btn

August 11, 2020

BridgeBio Pharma Expands Reach Into China and Other Major Asian Markets Through Strategic Collaboration With Perceptive Advisors-Founded Company, LianBio

arrow-btn

August 11, 2020

Perceptive Advisors Launches LianBio with Multiple Strategic Alliances and Establishes Operating Platform

arrow-btn